Day: April 13, 2020

RALEIGH, N.C., April 13, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2020 results after the market closes on Thursday, April 30, 2020. The Company will also host a conference call on Friday, May 1, 2020 at 9:00 a.m. (ET) to discuss the results with members of the investment community.To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 7450977. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 7450977.A live audio broadcast will be available...

Gaithersburg, MD, April 13, 2020 (GLOBE NEWSWIRE) — Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS)) today announced financial results for its fiscal 2019 fourth quarter and fiscal year ended October 31, 2019. In conjunction with this release, the Company is also providing additional details on its strategy for the upcoming fiscal 2020 financial year.For Q4 2019, revenue set an all-time record of $4.7 million, an increase of 116% over the $2.2 million reported in Q4 2018.For fiscal 2019, management is noting the following items of importance:Revenue set an all-time record of $13.6 million, an increase of 135% over the $5.8 million reported in fiscal 2018.Gross profit margin was 15.2%, approximately 230 basis-points higher than the 12.9% reported in fiscal 2018.Operating expenses of $6.2 million were $3.2 million...

Conference Call Scheduled for 8:30 a.m. Eastern TimeWEST PALM BEACH, Fla., April 13, 2020 (GLOBE NEWSWIRE) — Affiliated Managers Group, Inc. (NYSE: AMG) will report financial and operating results for the first quarter ended March 31, 2020 on Monday, April 27, 2020. A conference call will be held at 8:30 a.m. Eastern time on the same day.                               In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President and Chief Executive Officer, and Thomas M. Wojcik, Chief Financial Officer, will host the session.Parties interested in listening to the conference call should dial 1-877-407-8291 (U.S. calls) or 1-201-689-8345 (non-U.S. calls) shortly before the call begins.The conference call will also be available...

NEW YORK, 13 avr. 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), une société biopharmaceutique de stade clinique spécialisée dans le développement d’immunothérapies fondées sur des cellules CAR-T allogéniques ingénierées (UCART), annonce la nomination de Carrie Brownstein, M.D., au poste de Directrice médicale. Le Dr Brownstein supervisera la recherche et le développement cliniques pour les programmes UCART de Cellectis en phase clinique. Le Dr Brownstein quitte Celgene pour rejoindre Cellectis, forte d’une solide expérience en hématologie et pathologies myéloïdes. Le Dr Brownstein est basée sur le site de Cellectis à New York et rejoint le comité exécutif de l’entreprise.« Nous sommes ravis que le Dr Brownstein apporte à Cellectis sa grande expertise industrielle et son remarquable leadership au moment...

SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera“) has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. (“Stero”), and that Stero and Kalytera have terminated the Letter of Intent relating to the acquisition.“Although Kalytera will not proceed with the acquisition of Stero, we are in active discussions with other companies to expand and diversify our operations,” stated Robert Farrell, the Company’s President and CEO.About Kalytera TherapeuticsKalytera Therapeutics, Inc. (“Kalytera“) seeks to establish a leading position in the development of novel medicines for a range of important unmet medical needs.Website Home: https://kalytera.co/News and Insights: https://kalytera.co/news/Investors: https://kalytera.co/investors/Cautionary...

RICHMOND, Va., April 13, 2020 (GLOBE NEWSWIRE) — Kinsale Capital Group, Inc. (NASDAQ: KNSL) announced today that it will release financial results for the first quarter of 2020 after the market closes on Thursday, April 30, 2020.The Company will host a conference call to discuss its results with analysts and investors on Friday, May 1, 2020, beginning at 9:00 a.m. (Eastern Time). The release will also be available on the Company’s website, www.kinsalecapitalgroup.com.To access the conference call, dial (844) 239-5282, conference ID# 4841629, or via the Internet by going to www.kinsalecapitalgroup.com and clicking on the “Investor Relations” link. Please visit the website at least 15 minutes before the call to register and download and install any necessary audio software. A replay of the call will be available on the website until...

BOULDER, Colo., April 13, 2020 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, will conduct a conference call on Monday, April 27, 2020, at 4:30 p.m. Eastern time (2:30 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2020. The company will report its financial results in a press release prior to the call.Gaia management will host the conference call, followed by a question and answer period.Date: Monday, April 27, 2020Time: 4:30 p.m. Eastern time (2:30 p.m. Mountain time)Toll-free dial-in number: (800) 263-0877International dial-in number: (646) 828-8143Conference ID: 9392365Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with...

NEW YORK, April 13, 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Carrie Brownstein, M.D., to the role of Chief Medical Officer. In Dr. Brownstein’s new role, she will oversee clinical research and development for Cellectis’ UCART clinical trial programs. Dr. Brownstein joins Cellectis from Celgene, with a strong track record in hematology and myeloid diseases. She is assuming her new position based in the Cellectis New York office and is joining the Company’s executive committee.“We are thrilled to have Dr. Brownstein bringing her strong industry expertise and impressive leadership at a time when our three proprietary product candidates...

SINGAPORE, April 13, 2020 (GLOBE NEWSWIRE) — Reebonz Holding Limited (the “Company” or “Reebonz”; Nasdaq: RBZ), a leading online luxury marketplace and platform in Asia Pacific, announced today that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) dated April 7, 2020 indicating that the Company did not meet the continued listing requirement of maintaining a minimum bid price of $1 per share for the Nasdaq Global Market, as set forth in the Nasdaq Listing Rule 5450(a)(1) because the bid price of the Company’s publicly held ordinary shares for the last 30 consecutive business days was below the minimum bid price requirement of US$1 per share.Pursuant to Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a compliance period of 180...

TORONTO, April 13, 2020 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) announced today its production and sales results for the first quarter of 2020.In the first quarter of 2020, Mandalay produced a consolidated 25,677 saleable ounces of gold equivalent and sold 24,276 ounces of gold equivalent.Dominic Duffy, President and Chief Executive Officer of Mandalay, commented, “The first quarter of 2020 showed a significant increase in both gold and antimony production as production from the high-grade Youle vein at Costerfield began to ramp up. Gold and antimony production increased 36% and 62%, respectively, compared to the fourth quarter of 2019.”Mr. Duffy continued, “The significant increase in production was driven by the excellent results from Costerfield....